

# CrayoNano Q4 2022 presentation

**16 February 2023** 

Disrupting the fast growing markets for disinfection



## **Presenters today**



Jo Uthus CEO



Jens Kielland CFO



## **Q4 Strategic Update**



## **About CrayoNano**

- Global presence with headquarters in Norway and facilities in Taiwan
- Pioneers in nanotechnology-based semiconductor components
- Strong technology IP portfolio with 266 patents (97 granted, 169 licensed from partner)
- Enabling Environmental, Social and corporate Governance (ESG) solutions with our partners
- Our first product line of radically efficient UV-C LEDs are vital components for the fast-growing disinfection markets
- Fab-lite business model utilising global supply chain





## **Q4 Highlights**

In Q4 we continued to deliver on our mission to develop nanomaterial-based semiconductors that contribute to solutions toward global environment and health challenges

### Successful launch of our first product

 On 6 October 2022, we launched the CrayoLED<sup>TM,</sup> an ultraviolet-C light emitting diode (UV-C LED) semi conductor packaged component

### First revenue booked

 CrayoNano generated first commercial revenue from the sale of initial test units to customers with further demand for our product remaining strong

## **Operational ramp up**

Testing of our production yields continues to ensure final production quality

### **Taiwanese operations**


• Completion of our 'Fab2' commission on budget as we transition to our 'fab-lite 'operating model

### **Private placement update**

 Ongoing plans to complete our planned private placement, followed by a listing on the Euronext Growth market



## UV-C LED market estimated growth of 40% CAGR to \$2.5bn by 2026



UV-C disinfection dates back to 1910, and used on a bigger scale since the mid 1950s



## Structured sales process

### Standard customer qualification and design-in process

Pilot product First product New vendor

benchmarking

~2-3 months

qualification ~4-9 months

Vendor qualification ~1-2 months

Order fulfilment ~1 week

Repeat business

### Typical qualification & design win timeline – 5-12 months



Sample Testing ~ 1 months

**Product Qualification** 3 - 9 months

Design Win Qualification 1 - 2 months

## **CrayoNano's revenue operations** (RevOps)



Holistic customer orientation

Sales / marketing / customers operations + Data The three teams work together as one unit to work with data, which fuels the RevOps strategy



Close customer follow-up

Netsuite's ERP/CRM system went live on July 1st with customer pipeline including forecast and opportunities implemented



## Strong customer demand in Q4, supporting 2023 targets



Strong attraction in Q4'22 post product launch, creating basis for 2023 targets

Note: 1 Leads – a new company with an interest in CrayoNano, 2 Prospect – a qualified lead with potential to become a customer or opportunity, 3 Opportunity - a prospect who we have discovered has potential quantifiable business with CrayoNano, 4 Quotes – budgetary quotes, 5 Design-in – customer is engineering, qualifying and performing next steps to incorporate CrayoNano into their product, 6 Design-wins with small volumes, 7 Accumulated until September 2022



## Key examples of CrayoLED™ design-ins for 2023



### Expect to ship 1 million pieces in 2023



## Positive customer feedback

## CrayoLED™ LED samples distributed to target customer groups



### CrayoLED™ H-series customer feedback

"CrayoLED<sup>TM</sup> initial testing results are **impressive**. Power and Voltage are matching the specs.  $3^{rd}$  party qualification highly appreciated" by tier-1 water disinfection OEM customer (US)

"CrayoNano, being a UV-C focused company is critical for us. Initial test results are good in terms of measurements and specs" by tier-1 water POE customer (UK)

"H-series is a **highly robust and reliable** UV-C LED with solid package. " by tier-1 system integrator (Taiwan)

"Would like to utilize CrayoLED in the product & promote it in India consumer market." by tier-1 ODM (India)

"We have been waiting for the transitional time since the early UV-C and we **finally see it with your LED**." by tier-2 OEM (US)

"We are buying other UVC LEDs right now. **The output of H-series is higher and lifetime is the same**. Price is similar too." by semiconductor Tier-1 customer

"Your **technical specification** in small, standardised form-factor and long life-time is already **taking UV-C LEDs one step further beyond your competitors**" – by Tier 1 customer



## CrayoNano Taiwan Fab2 – enabling our fab-lite strategy

### **Fab-lite strategy**

Own R&D lab in Norway



CrayoNano wafer fab + partner foundry in Taiwan

### 3,000m<sup>2</sup>

available for in-house development in partner foundry, 500m<sup>2</sup> dedicated to CrayoNano fab2

### Lower time to market

allows CrayoNano to focus on cost optimisation and control of the supply chain and intellectual property

20m units per year

## **Increased flexibility**

can lease 1 machine for NOK 2-300k/month - total manufacturing capacity of

### Taiwan key for accelerating fab-lite strategy



Increased activities toward Taiwan to scale operations



Geographically strategic for supply chain management



Concentration of semiconductor talent and industrial know-how










## CrayoLED™ UV-C LED Product Line



Clean UV-C output, High germicidal efficacy



High flux density 3.5 x 3.5mm



Robust packaging



Parameter (Typical)	Symbol	Value	Unit
Peak Wavelength	$\lambda_{P}$	275	nm
Radiant Flux	$P_{O}$	80	mW
Forward Voltage	$V_{F}$	6	V
Spectrum Half-width	Δλ	11	nm
Viewing Angle	2Φ <sub>1/2</sub>	120	degrees
Thermal Resistance (junction – solder point)	$R_{\Theta JS}$	6	K/W







CrayoLED™ H-series (CLH-N3S) is available in both sample quantities and in stock for volume production



## **Financial Update**



## Q4 2022 and full year Financial results

### **Profit and loss**

### NOK million


	Q4 2022	Q4 2021	2022	2021
Sales revenue	0.2	0.0	0.4	0.0
Other revenue	0.2	2.0	7.6	8.3
Revenue	0.4	2.0	8.0	8.3
COGS	0.1	0.0	0.2	0.3
Payroll and related costs	6.4	8.6	35.0	27.3
Other operating costs	16.0	3.3	41.4	15.7
EBITDA	-22.1	-9.9	-68.6	-34.9
Depreciation & Amortization	2.1	1.5	7.3	6.0
EBIT	-24.2	-11.4	-75.9	-40.9
Net financial items	0.1	-0.1	- 0.6	- 0.2
Net profit before tax	-24.1	-11.5	-76.5	-41.1

### **Comments**

- Sales revenue of NOK 0.2m in the quarter from initial pilot volume shipments to our first customers
- Total operating cost increased to 22.4m, up from 11.9m in Q4 2021, driven by an increase in strategic partner R&D activities, scaling of operations and Taiwan Fab2
- Negative EBITDA of NOK 22.1m in Q4 2022 compared to NOK 9.9m in Q4 2021



## Investing to support accelerated growth plan



### **Comments**

- Negative cash flow from operations of NOK 24.1m in the quarter, a spending increase of NOK 2.6m quarter-on-quarter and NOK 12m year-on-year
  - Started to build strategic inventory
  - Increased spending in Fab 2 related to the cleanroom installation, equipment and infrastructure
- Decrease in net change in cash and cash equivalents NOK 29.8m in Q4 2022 vs. NOK 18m in Q3 2022 and NOK 15.7m in Q4 2022
  - Increased investments in R&D and no public funding received in the quarter
- Cash balance at year-end of NOK 10.2m, shareholder loan of NOK 27.5 increased cash balance to NOK 28.4m at the end of January 2023



## Capital markets update

### **Strong commitment**

- Signed a loan agreement in January 2023 with our three largest shareholders totalling NOK 27.5m
- The loan will be converted to equity given successful private placement
- EIC fund signed term sheet of c.NOK 50m extended to 31st March 2023
- Cash balance of NOK 28.4m at the end of January

### **Private placement**

- Growth capital will be used to support the ongoing acceleration plan including high volume production
- Process expected to close soon, details to follow

### **Listing Process / Euronext Growth update**

Prepared to list on Euronext Growth when the timing is right



**Q4** Key Takeaways

## Q4 key takeaways

Ongoing commercial engagement

Operational readiness and supply chain

**Funding our growth** 

Reached out to 100+ customers [Customers point from op update]

Positive feedback from customers [update]

First revenue booked in the quarter and optimistic of the continued growth of product use and application

Completion and commencement of operations of our 'Fab2' in Taiwan Built strategic inventory of products based on customer orders

Very strong commitments from 3 largest shareholders with NOK 27.5m loan converted to equity on equal terms in the placement

Private Placement process ongoing, expected to close soon

Euronext Growth markets listing to take place shortly thereafter





Q&A



## Appendix



## P&L

## **Condensed profit and loss statement** (unaudited)

	Q4	Q4	FY	FY
(Figures in NOK thousands)	2022	2021	2022	2021
Sales revenue	230	0	438	0
Other revenue and public grants	211	1 984	7 559	8 326
Total revenues	441	1 984	7 997	8 326
COGS	133	0	236	289
Payroll and related costs	6 412	8 635	34 993	27 260
Other operating costs	15 982	3 282	41 378	15 655
EBITDA	-22 086	-9 933	-68 611	-34 879
Depreciation	2 110	1 503	7 253	6 007
EBIT	-24 196	-11 436	-75 864	-40 886
Net financial items	52	- 60	- 633	- 215
Net profit before tax	-24 144	-11 496	-76 497	-41 101
Tax expense	-5 254	-3 223	-17 145	-9 737
Net profit (loss)	-18 890	-8 273	-59 351	-31 364
# shares in 1000	28 401	28 401	28 401	28 401
Earnings pr share (NOK)	-0.67	-0.29	-2.09	-1.10

Note: P&L presented is net of capitalized R&D



## **Balance sheet**

Condensed balance sheet		
(unaudited)	FY	FY
(Figures in NOK thousands)	31/12/2022	31/12/2021
Assets		
Development, patents and licenses	64 692	58 581
Deferred tax assets	43 371	25 909
Tangible fixed assets	12 735	14 042
Financial fixed assets	1 059	2 061
Total non-current assets	121 857	100 593
Current assets		
Inventory	2 087	0
Trade and other receivables	16 896	6 093
Cash and cash equivalents	10 238	100 092
Total current assets	29 221	106 185
Total assets	151 078	206 778
Equity and liabilities		
Equity		
Share capital	568	568
Share premium account	104 665	234 362
Additional paid-in capital	2 596	2 596
Retained earnings	0	-69 224
Total equity	107 829	168 302
Liabilities		
Liabilities to finance institutions	8 073	10 593
Trade payables	9 239	3 518
Government charges	2 277	1 486
Other liabilities	23 659	22 878
Total liabilities	43 249	38 476
Total equity and liabilities	151 078	206 778

Disclaimer:
The contents and material in this presentation, (including but not limited to designs, data, images, audios, videos and trademarks) is the property of CrayoNano or its licensors. Such content and material is protected by intellectual property laws and marketing laws and not intended to be distributed to any third party without the written consent of CrayoNano.
The information contained herein may be inaccurate or contain errors, and no representation or warranty is made as to the accuracy, correctness or completeness of the information provided. Any use or reliance upon such information is at the sole risk and responsibility of the user. CrayoNano will not accept liability for any such use or reliance. In particular, the content herein is not meant or expected to be used or relied upon as investment, financial, legal, or other advice. Each user should obtain its own independent advice in relation to the information provided herein.

Disrupting the fast growing markets for disinfection



## CrayoNano AS

Sluppenvegen 6, Trondheim, Norway +47 72 92 98 60 investor@crayonano.com